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main branch with regular balloon for the side branch did not show
signiﬁcant improvement at 6/12 follow up particularly for the side
branch which still show signiﬁcant rate of restenosis. In bifurcation
lesion with signiﬁcant stenosis of both branches, the restenosis of side
branch is high with either provisional or two stent techniques (15%).
Recent reports suggest that drug eluting balloon (DEB) might improve
the current result of side branch treatment. We perform this study to
evaluate outcome of the percutaneous coronary intervention (PCI)
with DES for main branch & DEB for side branch with bifurcational
coronary artery disease.
METHODS This study enrolled 80 patients with coronary artery bifur-
cation lesions, 50 were males & 30 were females with a mean age of
608 years. Thirty patients had hyperlipidemia and 48 had diabetes
mellitus. The involved vessels included left anterior descending/diag-
onal (56), circumﬂex/obtuse marginal (16) and right coronary artery/
posterior descending or posteriolateral (8). All patients receivedDES for
main branch PCIwith paclitaxel DEB for the side branch. 50 patients had
stable angina and 30 had unstable angina or silent ischemia. Patients
with left main bifurcational lesion and patient with severe left ven-
tricular dysfunction (ejection fraction > 25%)were excluded. At 6
months follow-up, coronary angiogram was performed in 40 patients,
nuclear image in 28 patients and the remaining 12 were followed-up
clinically. The mean size and length were 2.75  0.5 and 18.0  6.0 mm
for the used DES and 2.22  0.23 and 18.0  8.0 mm for the used DEB.
RESULTS Procedure success was achieved in all patients. The Pre-PCI
diameter stenoses for themain branch and for the side branchwere 85
12% and 8010%, respectively. They became 57% and 1510% imme-
diately after the procedure and 156% and 3010% at 6-12 month
follow-up. Dissection of the posterolateral branch with residual reste-
nosis of 60% occurred in one patient during dilatation with DEB, which
was treatedwithDESwith good result. No acute or sub-acute thrombosis
was noticed in any of the studied patients. The incidences of restenosis
and of major adverse cardiac events at follow-up were 5% and 6.25%,
respectively. Restenosis occurred in 2 patients with circumﬂex/obtuse
marginal and in 2 patients with left anterior descending /diagonal dila-
tation. 2 were treated with coronary artery bypass surgery and the other
twowere treatedmedically. No deathwas observed in any of the studied
patients during the 12 month follow-up period.
CONCLUSION This study demonstrates that the technique of using
DES for the main branch and DEB for the side branch for the treatment
of bifurcational lesions is safe and effective with a low incidence of
restenosis and major adverse cardiac events at immediate and six-
twelve months follow-up.
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BACKGROUND The aim of this study was to compare the impact on
clinical outcome of unprotected left main coronary artery (ULMCA)
aorto-ostial coverage (AOC) with DES.
METHODS A total of 3041 patients with signiﬁcant ULMCA
stenosis were enrolled in ASAN-MAIN registry. We identiﬁed 861
(28.3%) with ULMCA treatment with DES, who were categorized into
stenting with AO coverage (AOC, N¼623) versus stenting without AOC
(N¼238).
RESULTS Angiographic follow up was obtained in 630 (73.1%) patient.
No AOC group showed more chronic total occlusion (2.9% vs. 1.0%;
p¼0.033) and more ulcerative lesions (4.6% vs.2.1%; p¼0.043). In
patients of the AOC group had more aorto-ostial lesion (49.3% vs.
2.1%; p¼ <0.001). During 2-year follow-up, all-cause mortality, MI,
TVR and TLR did not show statistically signiﬁcant differences. LM ISR
did not differ between groups (4.2% in No AOC group vs. 6.9% in AOC
group; p¼0.29).LM ostial ISR occurred 8 patients (1.28%) in AOC group
and de novo LM ostial stenosis occurred 4 patients (1.68%) in No AOC
group. After Cox regression multivariable analysis, AOC did not affect
the cardiac death (HR 1.86, 95% CI 0.57 to 6.05; p¼ 0.30).
CONCLUSION AOC of the ULMCA with DES is safe, which did not
affect clinical outcomes or ISR.Table 1. Characteristics of Study Patients Undergoing PCI of the ULMCANo AOC (N[238) AOC (N[623) P-valueAge (years) 62.3410.97 63.929.47 0.231Gender (Male) 45(18.9) 174(27.9) 0.007Hypertension 144(60.5) 356(57.1) 0.371Diabetes 85(35.7) 216(34.7) 0.774LV ejection fraction (%) 57.39.72 59.67.64 0.035Aorto-ostial lesion 5(2.1) 307(49.3) 0.001At least one chronic total occlusion 7(2.9) 6(1) 0.033At least one severe calciﬁcation 14(5.9) 21(3.4) 0.095At least one thrombus present 12(5) 26(4.2) 0.579At least one ulceration 11(4.6) 13(2.1) 0.043Reference diameter (mm) 3.580.44 3.70.42 0.001Lumen diameter stenosis (%) 61.8332.8 64.7926.5 0.171Total number of stents 2.891.4 2.681.5 0.301Total stent length 70.3239.7 63.0838.1 0.158Maximal balloon inﬂation size 3.940.3 4.080.4 0.004Data are N (%), meanSD); AOC, aorto-ostial coverage
(Freedom From All-cause Mortality in the AOC Group Versus the No
AOC Group for ULMCA).CELL THERAPY AND ANGIOGENESIS (TCTAP A-041)
TCTAP A-041
Inhibiting Mobilization of Ly6Chigh Monocytes After Acute Myocardial
Infarction Enhanced the Efﬁcacy of Mesenchymal Stromal Cells
Transplantation and Curbed Myocardial Remodeling
Wenbin Lu,1 Fu Cong,1 Wang Xin,1 Genshan Ma1
1Zhong Da Hospital, Southeast University, China
BACKGROUND Ischemia-related inﬂammation is the most critical fac-
tor for the survival of transplanted mesenchymal stem cells (MSCs).
Strategies of keeping excessive inﬂammation in control after acute
myocardial infarction (AMI) are necessary and essential for the survival
of transplanted MSCs. Our study was to test whether decreased
Ly6Chigh monocytes beneﬁted mouse MSCs transplantation post-AMI.
METHODS BALB/c AMI mice were systemically treated with CCR2
antagonist (RS504393, 2mg/kg, Tocris) or normal saline (controlgroup).
105 EdU-labeled (Invitrogen) MSCs were administered to mice in both
groups by intramyocardial injection.We used Tunel kits (R&D Systems)
to identify the apoptotic cardiomyocytes in the infarct zone. And slides
of the infarcts were stainedwithWheat GermAgglutinin (Invitrogen) to
measure vessel density. Anti-Myosin Heavy Chain eFluor 660 (eBio-
science) was utilized to measure cardiac myosin-positive area. Trans-
well chambers (Corning) were introduced to examine the interactions
between MSCs and Ly6Chigh monocytes. Inﬂammatory cytonkines
expressed by Ly6Chigh monocytes and SDF-1 secreted by MSCs were
detected with Elisa Kits (R&DSystems). MSCs viability was further
